Details of the Drug

General Information of Drug (ID: DMCSEUY)

Drug Name

ALN-TTR01

Indication

Disease Entry	ICD 11	Status	REF
Amyloidosis	5D00	Phase 1	[1]
Transthyretin familial amyloid cardiomyopathy	5D00.20	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Antisense oligonucleotide

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Transthyretin messenger RNA (TTR mRNA)	TTPOYU7	TTHY_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
2	ClinicalTrials.gov (NCT01148953) Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis. U.S. National Institutes of Health.
3	Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013 Aug 29;369(9):819-29.